Format

Send to

Choose Destination
Contemp Clin Trials. 2015 Nov;45(Pt B):443-448. doi: 10.1016/j.cct.2015.09.023. Epub 2015 Oct 3.

Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients.

Author information

1
Department of Medicine, Division of General Internal Medicine,University of CaliforniaSan Francisco, USA; Helen Diller Family Comprehensive Cancer Center,University of CaliforniaSan Francisco, USA. Electronic address: celia.kaplan@ucsf.edu.
2
Department of Medicine, Division of General Internal Medicine,University of CaliforniaSan Francisco, USA; Helen Diller Family Comprehensive Cancer Center,University of CaliforniaSan Francisco, USA.
3
Helen Diller Family Comprehensive Cancer Center,University of CaliforniaSan Francisco, USA.
4
Department of Medicine, Division of General Internal Medicine,University of CaliforniaSan Francisco, USA.
5
Department of Psychiatry,University of CaliforniaSan Francisco, USA.
6
Radiation Oncology, University of California, San Francisco, USA.
7
Helen Diller Family Comprehensive Cancer Center,University of CaliforniaSan Francisco, USA; Department of Medicine, Division of Hematology and Oncology,University of CaliforniaSan Francisco, USA.

Abstract

BACKGROUND:

Enrollment of minorities in clinical trials remains low. Through a California population-based study of men with early stage prostate cancer, we examined the relationships between race/ethnicity and 1) attitudes, 2) knowledge and 3) willingness to participate in clinical trials.

METHODS:

From November 2011-November 2012, we identified all incident cases of prostate cancer in African American, Latino, and Asian American men ages 18-75 years, and a random sample of white men diagnosed in 2008, through the California Cancer Registry, living within 60 miles of a site offering ≥ 1 clinical trial. Participants completed a 30-min telephone interview in English, Spanish, or Chinese. In this cross-sectional population-based study, multivariable logistic regression was used to estimate associations between race/ethnicity and 1) attitudes, 2) knowledge and 3) willingness to participate.

RESULTS:

Of 855 participants, 52% were ≥ 65 years, 42% were white, 24% Latino, 19% African American and 15% Asian American. The majority (81%) had medium-to-high health literacy. Compared to non-Latino white men, African American men were less likely to have above average knowledge of clinical trials (OR=0.55; CI=0.35-0.86), as were Asian American (OR=0.55; CI=0.33-0.93) and Latino men (OR=0.30; CI=0.18-0.48). There were no racial/ethnic differences in willingness to participate. The attitude that "researchers are the main beneficiaries" was negatively associated with willingness (OR=0.63; CI=0.43-0.93); the attitude that "patients are the main beneficiaries" was positively associated with willingness to participate (OR=1.57; CI=1.07-2.29).

CONCLUSIONS:

Men with early stage prostate cancer are willing to take part in clinical trials and this willingness does not vary by race/ethnicity.

KEYWORDS:

Clinical trials participation,; Prostate cancer

PMID:
26435199
DOI:
10.1016/j.cct.2015.09.023
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center